{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:03:30Z","timestamp":1766088210452},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,14]]},"DOI":"10.7759\/cureus.54202","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:33:46Z","timestamp":1707950026000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Duodenal Adenocarcinoma With Brain Metastasis"],"prefix":"10.7759","author":[{"given":"Hariharasudan","family":"Mani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alisha","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018","author":"Noone AM","year":"2018","unstructured":"Noone AM, Howlader N, Krapcho M, et al.. SEER Cancer Statistics Review, 1975-2015, based on November 2017 SEER data submission, posted to the SEER web site, April 2018. Bethesda, MD: National Cancer Institute; 2018."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria KY","year":"2009","unstructured":"Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009, 249:63-71. 10.1097\/SLA.0b013e31818e4641","journal-title":"Ann Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20404","article-title":"Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients","volume":"101","author":"Dabaja BS","year":"2004","unstructured":"Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004, 101:518-26. 10.1002\/cncr.20404","journal-title":"Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/DCR.0000000000000562","article-title":"Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer","volume":"59","author":"Young JI","year":"2016","unstructured":"Young JI, Mongoue-Tchokote S, Wieghard N, Mori M, Vaccaro GM, Sheppard BC, Tsikitis VL. Treatment and survival of small-bowel adenocarcinoma in the United States: a comparison with colon cancer. Dis Colon Rectum. 2016, 59:306-15. 10.1097\/DCR.0000000000000562","journal-title":"Dis Colon Rectum"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v10.i22.3345","article-title":"Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival","volume":"10","author":"Bartelt S","year":"2004","unstructured":"Bartelt S, Momm F, Weissenberger C, Lutterbach J. Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. World J Gastroenterol. 2004, 10:3345-3348.","journal-title":"World J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le DT","year":"2015","unstructured":"Le DT, Uram JN, Wang H, et al.. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015, 372:2509-20. 10.1056\/NEJMoa1500596","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman MJ","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017, 18:1182-91. 10.1016\/S1470-2045(17)30422-9","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman MJ","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KY, et al.. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018, 36:773-9. 10.1200\/JCO.2017.76.9901","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15","article-title":"Antitumor activity of dostarlimab in patients with mismatch repair-deficient\/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study","volume":"39","author":"Berton D","year":"2021","unstructured":"Berton D, Banerjee SN, Curigliano G, et al.. Antitumor activity of dostarlimab in patients with mismatch repair-deficient\/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. J Clin Oncol. 2021, 39:2564-2564. 10.1200\/JCO.2021.39.15","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx688","article-title":"Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer","volume":"29","author":"Overman MJ","year":"2018","unstructured":"Overman MJ, Adam L, Raghav K, et al.. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018, 29:139-44. 10.1093\/annonc\/mdx688","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, et al.. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018, 378:731-9. 10.1056\/NEJMoa1714448","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO- 001): a phase 1\/2, open- label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B, et al.. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO- 001): a phase 1\/2, open- label, basket trial. Lancet Oncol. 2022, 23:1261-1273.","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease","volume":"19","author":"Overman MJ","year":"2012","unstructured":"Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012, 19:1439-45. 10.1245\/s10434-011-2173-6","journal-title":"Ann Surg Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3371-0","article-title":"Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer","volume":"80","author":"Takayoshi K","year":"2017","unstructured":"Takayoshi K, Kusaba H, Uenomachi M, et al.. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017, 80:333-42. 10.1007\/s00280-017-3371-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4274\/tjcd.galenos.2020.2020-4-15","article-title":"Small bowel adenocarcinoma presenting with brain metastasis","volume":"30","author":"Jorani I","year":"2020","unstructured":"Jorani I, Isik O. Small bowel adenocarcinoma presenting with brain metastasis. Turk J Colorectal disease. 2020, 30:205-207. 10.4274\/tjcd.galenos.2020.2020-4-15","journal-title":"Turk J Colorectal disease"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01219-z","article-title":"Brain metastases in gastroesophageal cancers-an underestimated complication","volume":"25","author":"Brunner M","year":"2022","unstructured":"Brunner M, Soll D, Adler K, et al.. Brain metastases in gastroesophageal cancers-an underestimated complication. Gastric Cancer. 2022, 25:161-9. 10.1007\/s10120-021-01219-z","journal-title":"Gastric Cancer"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38199","article-title":"Duodenal adenocarcinoma with suspected brain metastasis","author":"Duhan S","year":"2023","unstructured":"Duodenal adenocarcinoma with suspected brain metastasis. 2023, 15.e38199. 10.7759\/cureus.38199"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.25259\/SNI_413_2019","article-title":"A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma","volume":"10","author":"Yamazawa E","year":"2019","unstructured":"Yamazawa E, Honma Y, Satomi K, et al.. A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma. Surg Neurol Int. 2019, 10:256. 10.25259\/SNI_413_2019","journal-title":"Surg Neurol Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2798-4","article-title":"Brain metastasis in gastroesophageal adenocarcinoma and HER2 status","volume":"138","author":"Limon D","year":"2018","unstructured":"Limon D, Gal O, Gordon N, et al.. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol. 2018, 138:315-20. 10.1007\/s11060-018-2798-4","journal-title":"J Neurooncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/222376-a-rare-case-of-duodenal-adenocarcinoma-with-brain-metastasis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T22:33:50Z","timestamp":1707950030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/222376-a-rare-case-of-duodenal-adenocarcinoma-with-brain-metastasis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.54202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,14]]}}}